Related Experiment Video
Updated: Feb 10, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Re: Beta Blockers and Improved Progression-Free Survival in Patients With Advanced HER2 Negative Breast Cancer
Gitte Vrelits Sørensen1, Deirdre P Cronin-Fenton, Henrik Toft Sørensen
1Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark, gitte@clin.au.dk Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark Breast Unit Surgical Department, Randers Regional Hospital, Randers, Denmark Department of Plastic and Breast Surgery, Aarhus University Hospital, Aarhus, Denmark Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, Department of Epidemiology, Rollins School of Public Health and Winship Cancer Institute, Emory University, Atlanta, GA Departments of Surgery and Biochemistry, Larner College of Medicine, University of Vermont, Burlington, VT.
No abstract available in PubMed .
Related Concept Videos
Cancer Survival Analysis
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Survival Tree
Building a Survival Tree
Constructing a...
Negative Regulator Molecules
Positive, Negative, and Zero Work

